AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37649617 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare worker occupation
Number of subjects: 13000
Study 37649695 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37650231 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutics for the treatment of early COVID-19, specific interventions not detailed.
Number of subjects: 0
Study 37650231 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study 37650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe immunocompromise
Number of subjects: 0
Study 37650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression
Number of subjects: 0
Study 37650232 — intervention group
Group type: COMPARATOR
Intervention: Nonimmunocompromised individuals
Number of subjects: 0
Study 37650230 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (mAbs)
Number of subjects: 2115
Study 37650230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2115
Study 37650233 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta variant infection
Number of subjects: 0
Study 37650233 — intervention group
Group type: EXPERIMENTAL
Intervention: All variants (post-peak viral load)
Number of subjects: 0
Study 37650233 — intervention group
Group type: EXPERIMENTAL
Intervention: First-phase viral decline
Number of subjects: 0
Study 37650233 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-phase viral decline
Number of subjects: 0
Study 37650233 — intervention group
Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 0
Study 37650234 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational agents (specific agents not detailed)
Number of subjects: 0
Study 37650234 — intervention group
Group type: COMPARATOR
Intervention: Pooled placebo control group
Number of subjects: 0
Study 37650236 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 506
Study 37650235 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment in outpatient trials
Number of subjects: 0
Study 37650235 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis methods (ANCOVA or MMRM) with singly imputed values
Number of subjects: 0
Study 37650235 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis methods (ANCOVA or MMRM) considering values <LLoQ as censored measurements
Number of subjects: 0
Study 37650237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 37650478 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective neck dissection (ND)
Number of subjects: 2820
Study 37650478 — intervention group
Group type: COMPARATOR
Intervention: Positron emission tomography (PET-CT) following chemoradiotherapy
Number of subjects: 2820
Study 37650664 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging treatment options for cervical dysplasia and early cervical cancer, specific interventions not detailed.
Number of subjects: 0
Study 37650734 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib + Bevacizumab
Number of subjects: 0
Study 37650734 — intervention group
Group type: COMPARATOR
Intervention: Niraparib alone
Number of subjects: 0
Study 37650754 — intervention group
Group type: EXPERIMENTAL
Intervention: Microablative fractional CO laser treatment
Number of subjects: 15
Study 37650759 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (17DD)
Number of subjects: 218
Study 37650806 — intervention group
Group type: EXPERIMENTAL
Intervention: High Ventilation Mode
Number of subjects: 0
Study 37650806 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Standard Ventilation Mode)
Number of subjects: 0
Study 37650808 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Number of subjects: 0
Study 37650808 — intervention group
Group type: COMPARATOR
Intervention: Best-practices Treatment as Usual (TAU)
Number of subjects: 0
Study 37650957 — intervention group
Group type: EXPERIMENTAL
Intervention: Small nidus group (< 3 cm)
Number of subjects: 90
Study 37650957 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stasis index in the feeding artery
Number of subjects: 90
Study 37650957 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stasis index in the draining vein
Number of subjects: 90
Study 37650957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower outflow gradient in the draining vein
Number of subjects: 90
Study 37650981 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation (APBI)
Number of subjects: 0
Study 37650981 — intervention group
Group type: COMPARATOR
Intervention: Preoperative RT
Number of subjects: 0
Study 37651075 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Syncope Pathway (CSP) intervention
Number of subjects: 1002
Study 37651075 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1002
Study 37651144 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based progression (PBP) training
Number of subjects: 30
Study 37651144 — intervention group
Group type: COMPARATOR
Intervention: Traditional simulation-based training (SBT)
Number of subjects: 30
Study 37651172 — intervention group
Group type: EXPERIMENTAL
Intervention: Roadmap 2.0 app
Number of subjects: 17
Study 37651172 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology interventions (PPIs)
Number of subjects: 17
Study 37651172 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver involvement
Number of subjects: 17
Study 37651172 — intervention group
Group type: EXPERIMENTAL
Intervention: Connectivity with other patients
Number of subjects: 17
Study 37651172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support intervention
Number of subjects: 17
Study 37651174 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to increase physical activity (PADL)
Number of subjects: 0
Study 37651174 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (group discussions and video presentations)
Number of subjects: 0
Study 37651202 — intervention group
Group type: EXPERIMENTAL
Intervention: AFQ056
Number of subjects: 110
Study 37651202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 37651209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Retinal Imaging
Number of subjects: 0
Study 37651209 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 37651261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus magrolimab
Number of subjects: 76
Study 37651261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus niraparib
Number of subjects: 76
Study 37651261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus tocilizumab
Number of subjects: 76
Study 37651261 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab monotherapy
Number of subjects: 76
Study 37651291 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and provider education
Number of subjects: 0
Study 37651291 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional dialysis units and community dialysis houses
Number of subjects: 0
Study 37651291 — intervention group
Group type: EXPERIMENTAL
Intervention: Home dialysis preference mandate and financial support
Number of subjects: 0
Study 37651291 — intervention group
Group type: EXPERIMENTAL
Intervention: Respite care and planned home-to-home transitions
Number of subjects: 0
Study 37651373 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TXA (20 mg/kg loading dose followed by 5 mg/kg/h continuous infusion)
Number of subjects: 0
Study 37651373 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose TXA (20 mg/kg loading dose followed by continuous infusion of normal saline)
Number of subjects: 0
Study 37651373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical volume of normal saline)
Number of subjects: 0
Study 37651373 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 37651465 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity clusters (Heart-liver-gastrointestinal) in males aged 81-90 years
Number of subjects: 14286
Study 37651465 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity clusters (Diabetes-cardiovascular) in females aged 81-95 years
Number of subjects: 14286
Study 37651465 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity clusters (Psychogeriatric) in females aged 81-95 years
Number of subjects: 14286
Study 37651465 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall severe infection in COVID-19 patients
Number of subjects: 14286
Study 37651465 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality in COVID-19 patients
Number of subjects: 14286
Study 37651553 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 8191
Study 37651553 — intervention group
Group type: COMPARATOR
Intervention: Aromatherapy, massage, and acupressure
Number of subjects: 8191
Study 37651553 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological and other non-pharmacological interventions
Number of subjects: 8191
Study 37651654 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-compressed chemotherapy
Number of subjects: 0
Study 37651655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV) + Carboplatin (1L treatment); TV 2 mg/kg + Carboplatin AUC 5 on day 1 every 3 weeks
Number of subjects: 142
Study 37651655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV) + Pembrolizumab (1L treatment); TV 2 mg/kg + Pembrolizumab 200 mg on day 1 every 3 weeks
Number of subjects: 142
Study 37651655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV) + Pembrolizumab (2L/3L treatment); TV 2 mg/kg + Pembrolizumab 200 mg on day 1 every 3 weeks
Number of subjects: 142
Study 37651655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV) + Bevacizumab; TV 2 mg/kg + Bevacizumab 15 mg/kg on day 1 every 3 weeks
Number of subjects: 142
Study 37651666 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cutoff membranes
Number of subjects: 0
Study 37651666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux membranes
Number of subjects: 0
Study 37651666 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis
Number of subjects: 0
Study 37651666 — intervention group
Group type: COMPARATOR
Intervention: Hemodiafiltration
Number of subjects: 0
Study 37651676 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMPEG plus Nivolumab (NIVO)
Number of subjects: 783
Study 37651676 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (NIVO) monotherapy
Number of subjects: 783
Study 37651844 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fumarate therapy
Number of subjects: 28
Study 37651844 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (healthy volunteers)
Number of subjects: 28
Study 37651942 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual pressure
Number of subjects: 90
Study 37651942 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 90
Study 37651942 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 37651975 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA plus piracetam
Number of subjects: 100
Study 37651975 — intervention group
Group type: COMPARATOR
Intervention: Piracetam alone (control group)
Number of subjects: 100
Study 37651979 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI Mediterranean diet
Number of subjects: 156
Study 37651979 — intervention group
Group type: COMPARATOR
Intervention: Low-GI Mediterranean diet
Number of subjects: 156
Study 37652068 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological Pupil index (NPi) assessment using automated pupillometry every 4 hours for the first 7 days after admission.
Number of subjects: 514
Study 37652068 — intervention group
Group type: EXPERIMENTAL
Intervention: NPi assessment
Number of subjects: 514
Study 37652094 — intervention group
Group type: EXPERIMENTAL
Intervention: Local budesonide therapy (budesonide and physiological saline nasal irrigations administered via three syringes of 20 ml in each nasal cavity in the morning and evening for 30 days)
Number of subjects: 123
Study 37652094 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar protocol without budesonide)
Number of subjects: 123
Study 37652136 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely-instructed home-based transcranial direct current stimulation
Number of subjects: 0
Study 37652258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 4541
Study 37652258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 4541
Study 37652258 — intervention group
Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 4541
Study 37652258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4541
Study 37652258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 4541
Study 37652303 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation pembrolizumab after PBT reRT for locoregional recurrences of NSCLC
Number of subjects: 22
Study 37652304 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 105
Study 37652304 — intervention group
Group type: COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 105
Study 37652356 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine Acceptance Intervention (VAI) training
Number of subjects: 0
Study 37652356 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 37652360 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session web-based intervention (Partners Connect)
Number of subjects: 408
Study 37652360 — intervention group
Group type: COMPARATOR
Intervention: Communication resources from the Gottman Institute website
Number of subjects: 408
Study 37652360 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFT workbook
Number of subjects: 408
Study 37652360 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based CRAFT
Number of subjects: 408
Study 37652360 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners Connect
Number of subjects: 408
Study 37652554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) 6 mg/kg intravenous at week 0 followed by 90 mg subcutaneous every 8 weeks from week 8 to week 24
Number of subjects: 51
Study 37652554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 37652593 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver interviews and infant health, growth and neurodevelopmental assessments at 6, 12 or 18 months
Number of subjects: 362
Study 37652593 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessments using standardised tools
Number of subjects: 362
Study 37652593 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct measurement of growth and health indicators
Number of subjects: 362
Study 37652593 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of neurological findings
Number of subjects: 362
Study 37652677 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal radiofrequency ablation (RFA) plus stenting
Number of subjects: 161
Study 37652677 — intervention group
Group type: COMPARATOR
Intervention: Stenting alone (control group)
Number of subjects: 161
Study 37652822 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1 at 6-10-14 weeks/fIPV at 6 weeks
Number of subjects: 1192
Study 37652822 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1 at 6-10-14 weeks/fIPV at 10 weeks
Number of subjects: 1192
Study 37652822 — intervention group
Group type: COMPARATOR
Intervention: mOPV1 at 6-10-14 weeks
Number of subjects: 1192
Study 37652822 — intervention group
Group type: COMPARATOR
Intervention: bOPV at 6-10-14 weeks
Number of subjects: 1192
Study 37652823 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Number of subjects: 911
Study 37652841 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based model for predicting 5-year weight loss trajectories after bariatric surgery
Number of subjects: 10231
Study 37652940 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO-Concentrate administered orally for 7 days
Number of subjects: 32
Study 37652940 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO-Concentrate incubated with cultured adult microbiota
Number of subjects: 32
Study 37652990 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized treatment arm (specific treatments not detailed in the abstract)
Number of subjects: 3513
Study 37653075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year partially supervised physical activity intervention (≥2.5 hours of intense physical activity/week)
Number of subjects: 151
Study 37653075 — intervention group
Group type: COMPARATOR
Intervention: Control group continued exercise as usual
Number of subjects: 151
Study 37653140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispecific antibodies targeting GPRC5D
Number of subjects: 3
Study 37653140 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular profiling of target genes
Number of subjects: 3
Study 37653203 — intervention group
Group type: EXPERIMENTAL
Intervention: LungCARE
Number of subjects: 66
Study 37653203 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 37653215 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1RA + Met (liraglutide, 1.2-1.8 mg/day + Met 1500 mg/day)
Number of subjects: 60
Study 37653215 — intervention group
Group type: COMPARATOR
Intervention: CPA/EE + Met (2 mg/day CPA and 35 μg EE + Met 1500 mg/day)
Number of subjects: 60
Study 37653218 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic low-dose hydrocortisone (HC)
Number of subjects: 0
Study 37653218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37653269 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE4 carriers in the AD group (51.4%)
Number of subjects: 197
Study 37653269 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE4 carriers in the AD/DLB group (72.4%)
Number of subjects: 197
Study 37653269 — intervention group
Group type: EXPERIMENTAL
Intervention: High years of education (YOE) subgroup in DLB
Number of subjects: 197
Study 37653269 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ42 levels in DLB ApoE4-positive demented patients
Number of subjects: 197
Study 37653269 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE4 presence
Number of subjects: 197
Study 37653269 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE4
Number of subjects: 197
Study 37653342 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.222
Number of subjects: 887
Study 37653342 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 887
Study 37653378 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PG)
Number of subjects: 32
Study 37653378 — intervention group
Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 32
Study 37653380 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Total Gastrectomy (MITG)
Number of subjects: 60
Study 37653380 — intervention group
Group type: COMPARATOR
Intervention: Minimally Invasive Proximal Gastrectomy (MIPG)
Number of subjects: 60
Study 37653397 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L ribociclib + fulvestrant
Number of subjects: 0
Study 37653397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37653422 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma interleukin-6 levels
Number of subjects: 128
Study 37653422 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 128
Study 37653422 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive status
Number of subjects: 128
Study 37653422 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 128
Study 37653447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Number of subjects: 7035
Study 37653460 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterion®
Number of subjects: 51
Study 37653460 — intervention group
Group type: EXPERIMENTAL
Intervention: Argos®
Number of subjects: 51
Study 37653460 — intervention group
Group type: EXPERIMENTAL
Intervention: IOLMaster® 700
Number of subjects: 51
Study 37653460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam® AXL
Number of subjects: 51
Study 37653460 — intervention group
Group type: EXPERIMENTAL
Intervention: OcuScan® RxP
Number of subjects: 51
Study 37653477 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Triage
Number of subjects: 0
Study 37653525 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) and stretching exercises
Number of subjects: 0
Study 37653525 — intervention group
Group type: COMPARATOR
Intervention: Sham High-Intensity Laser Therapy (sham HILT) and stretching exercises
Number of subjects: 0
Study 37653536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Child Emotional Preparation (MCEP)
Number of subjects: 8
Study 37653607 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical fixation
Number of subjects: 64
Study 37653607 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 64
Study 37653641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's milk (analyzed for cytokines and inflammatory markers)
Number of subjects: 92
Study 37653641 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool calprotectin levels (corresponding to milk samples)
Number of subjects: 92
Study 37653767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cecal retroflexion during colonoscopy
Number of subjects: 55
Study 37653767 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 forward examinations only)
Number of subjects: 55
Study 37653767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cecal retroflexion
Number of subjects: 55
Study 37653768 — intervention group
Group type: EXPERIMENTAL
Intervention: PP6M (700/1000 mg eq.)
Number of subjects: 90
Study 37653768 — intervention group
Group type: COMPARATOR
Intervention: PP3M (350/525 mg eq.)
Number of subjects: 90
Study 37653768 — intervention group
Group type: EXPERIMENTAL
Intervention: PP6M
Number of subjects: 90
Study 37653768 — intervention group
Group type: COMPARATOR
Intervention: PP3M
Number of subjects: 90
Study 37653830 — intervention group
Group type: EXPERIMENTAL
Intervention: Preanesthesia assessment clinic (PAC)
Number of subjects: 30351